These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Resistance to treatment in gastrointestinal stromal tumours: what radiologists should know.
    Author: Tirumani SH, Jagannathan JP, Hornick JL, Ramaiya NH.
    Journal: Clin Radiol; 2013 Aug; 68(8):e429-37. PubMed ID: 23622797.
    Abstract:
    Gastrointestinal stromal tumour resistance to treatment with imatinib occurs due to pre-existing or acquired mutations. Computed tomography and positron-emission tomography play an essential role in prompt recognition of resistance to treatment. Primary resistance to treatment, which is encountered in the first 6 months of treatment, is associated with specific mutations. Imaging of these tumours shows no anatomical or metabolic response to treatment. Secondary resistance to treatment, which develops after an initial response, is associated with a variety of mutations acquired after the start of treatment. Imaging findings of secondary resistance are of disease progression.
    [Abstract] [Full Text] [Related] [New Search]